Oct 02nd 2013 - Edison Investment Research today published a report on Futura Medical (FUM.L, LSE:FUM, LON:FUM) entitled "Commercialisation Within Reach". In summary, the report says:
Futura Medical is approaching a key inflection point as its principal product is set for market launch. CSD500, a performance-enhancing condom, is licensed to Church & Dwight, the US consumer group that owns the Trojan brand. The low-cost business model means that even a modest success could prove transformational for the company’s finances. Our valuation is £66m, or 85p per share.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »